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Abstract: Obstructive sleep apnea syndrome (OSAS) is a complex chronic clinical syndrome, characterized by snoring, 
periodic apnea, hypoxemia during sleep, and daytime hypersomnolence. It affects 4-5% of the general population. Racial 
studies and chromosomal mapping, familial studies and twin studies have provided evidence for the possible link between 
the OSAS and genetic factors and also most of the risk factors involved in the pathogenesis of OSAS are largely geneti-
cally determined. A percentage of 35-40% of its variance can be attributed to genetic factors. It is likely that genetic fac-
tors associated with craniofacial structure, body fat distribution and neural control of the upper airway muscles interact to 
produce the OSAS phenotype. Although the role of specific genes that influence the development of OSAS has not yet 
been identified, current researches, especially in animal model, suggest that several genetic systems may be important. In 
this chapter, we will first define the OSAS phenotype, the pathogenesis and the risk factors involved in the OSAS that 
may be inherited, then, we will review the current progress in the genetics of OSAS and suggest a few future perspectives 
in the development of therapeutic agents for this complex disease entity.  
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INTRODUCTION 
Definition 
 The obstructive sleep apnea syndrome (OSAS) is a po-
tentially disabling condition, characterized by excessive day-
time sleepiness, disruptive snoring, recurrent episodes of 
apnea (no airflow) or hypopnea (partially obstructed air-
flow), and nocturnal hypoxemia, generally defined as five or 
more apneas–hypopneas per hour of sleep (i.e., the apnea–
hypopnoea index-AHI). 
 OSAS is usually associated with a history of habitual 
snoring, which is a sign of increased pharyngeal airflow re-
sistance. An OSAS is defined as an AHI, equal to or more 
than 5 accompanied by either excessive daytime sleepiness 
or two or more of episodes of choking or gasping during 
sleep, recurrent awakenings, unrefreshing sleep, daytime fa- 
tigue, or impaired concentration or memory [1]. The Ameri-
can Academy of Sleep Medicine classification of OSAS se-
verity considers both the AHI (mild defined as an AHI of 5–
15, moderate as 15–30, and severe as >30) and the degree of 
daytime sleepiness (mild: unwanted sleepiness or involun-
tary sleep episodes occurring during activities that need little 
attention; moderate: during activities that need some atten-
tion, such as during meetings; severe: during activities that 
need more active attention such as during conversation or 
driving). However, these thresholds are arbitrary [2]. 
 OSAS must be considered as a multifactorial disease. 
Multiple genes, environmental influences, and development  
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factors are closely related to OSAS. Redline and Tishler [3] 
emphasize on the genetic basis of several risk factors for 
obstructive sleep apnea. These risk factors include obesity, 
central control of ventilation, and craniofacial morphology. 
Probably for this reason, symptoms of sleep apnea syndrome 
have been found to be more common in the families of pa-
tients with this syndrome. 
Epidemiology 
 OSAS was first identified only 40 years ago and its clini-
cal importance is increasingly recognized. Although now 
acknowledged as a worldwide problem, which affects 2-4% 
of middle-aged men and 1-2% of middle-aged women in 
Western countries, the majority of affected individuals re-
main undiagnosed. OSAS is strongly associated with obesity 
currently occurring in many countries, but is also increas-
ingly identified in normal subjects, in whom a particular cra-
niofacial structure is an important contributory factor [4, 5].  
 OSAS is two to three-times more common in men than in 
women, and in those aged 65 years or more than in those 
aged 30–64 years. 
 In postmenopausal women, the OSAS prevalence tends 
to increase, particularly in women without hormone re-
placement therapy, but it remains lower than men of the 
same age stratum [6]. Although OSAS mainly affects adult 
subjects, its presence in children should not be neglected. 
This is not only because of its relatively high prevalence (2% 
in children aged 2–8 years, apparently related to adenotonsil-
lar hypertrophy), but also because of its clinical conse-
quences, including hypertension, nocturnal enuresis, growth 
retardation, cognitive impairment, and hyperactivity [7]. 
Excessive daytime sleepiness is reported to be associated 
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with a higher risk of motor vehicle accidents and work place 
injuries or poor work performance [8].  
Diagnosis of OSAS 
Clinical Picture 
 OSAS is characterized by several signs and symptoms. 
All of these can be divided into “nocturnal” and “daytime” 
symptoms. 
Nocturnal Symptoms 
 Snoring: Snoring is the most frequent symptom of 
OSAS. It is caused by the narrowing of the upper airway and 
occurs in up to 95% of patients. Anyway, it has poor predic-
tive value for the high prevalence in the general population. 
In fact, more than 60% of men and 40% of women aged be-
tween 41 and 65 years, snore during the night [4, 9]. 
 Witnessed Apnoeas and Restlessness: For a good 
evaluation of patient with suspected OSAS, it is advanta-
geous to interview the bed partner who can provide impor-
tant information about characteristics and the frequency of 
breathing pauses during sleep. It is considered as a good di-
agnostic predictor of OSAS [4]. 
 Nocturnal Choking or Gasping: Some patients report 
waking at night with a choking sensation that passes after 
few seconds.  
 Other Nocturnal Symptoms: Patients with OSAS less 
frequently report nicturia, excessive salivation, sleep frag-
mentation, arousals and gastro-esophageal reflux [10]. 
Daytime Symptoms 
 Excessive Daytime Sleepiness: Obstructive sleep apnea 
is the most common sleep disorder that causes excessive day-
time sleepiness (EDS). It leads to day time fatigue, decreased 
concentration, and an increased risk of traffic accidents.  
 Other Daytime Symptoms: Many patients also report 
headache, memory impairment, and depression [10]. 
Questionnaires  
 Currently, a limited number of screening tools are avail-
able to detect sleep disorder in adults. The Berlin question-
naire [11], which was designed to identify patients as being 
at ‘high’ or ‘low’ risk for OSAS, assesses the patient’s risk 
level based on approximately 11 questions addressing three 
symptom categories: snoring, sleepiness, and high blood 
pressure/weight. The Sleep Disorders Questionnaire (SDQ) 
is a valid tool to diagnose common sleep disorders, but due 
to its length (176 items) the author concluded that is not a 
practical instrument in primary settings [12]. The Pittsburgh 
Sleep Quality Index (PSQI) is a 24-item questionnaire useful 
for measuring changes in sleep quality over time in patients, 
alerting physicians for the need of further evaluation [13] 
Roth et al. purposed the Global Sleep Assessment Question-
naire (GSAQ) as a suitable screening tool for sleep disorders 
in general primary care population, although the author de-
clared some study-limitations [11]. More recently some 
authors have purposed the SA-SDQ, a 12-item validated 
measure of sleep related breathing disorders, as a possible 
useful tool to screen epilepsy patients for OSAS, although 
appropriate cut-off points have not been established. In a 
recent work, we purposed the usefulness of a 7-items ques-
tionnaire, Rome Questionnaire (RQ), in identifying adult 
patients at risk of OSAS. The "RQ", together with BMI, 
seems to be a useful tool to make a selection of the patients 
at higher risk of moderate-severe OSAS, who need a prompt 
PSG evaluation [14]. 
Polysomnography (PSG) 
 Sleep laboratory for overnight polysomnography (PSG) 
is the gold standard diagnostic tool for patients with sus-
pected sleep apnea. This procedure includes continuous re-
cordings of many physiologic data including airflow, 
chest/abdominal excursion, electroencephalography, electro-
oculography, electromyography, electrocardiography, and 
oxyhemoglobin saturation. However, PSG in the sleep labo-
ratory is expensive, cumbersome, and not readily available in 
many geographic areas due to a growing demand for the pro-
cedure. Portable monitoring device based on a limited num-
ber of channels in an ambulatory setting such as the home 
could improve access to care and reduce costs. The Ameri-
can Sleep Disorders Association (ASDA) has classified di-
agnostic systems into four categories, based on the testing 
environment, technician attendance, and number of parame-
ters recorded [15]. Level I is reserved for technician-attended 
in-laboratory PSG. Portable monitoring ranges from level II 
(unattended, full polysomnography) to level IV (single chan-
nel such as simple pulse oxymetry). ASDA level III is re-
served for devices that monitor airflow, chest/abdominal 
excursion, heart/pulse rate, and oxyhemoglobin saturation. 
More recently proposed methods for quantification of OSAS 
are the cross-power index (CPI, the integral of the cross-
spectrum modulus between concomitant fluctuations in sys-
tolic blood pressure and blood oxygen saturation), aimed to 
assess the cardiovascular impact of OSAS, and the periph-
eral arterial tonometry index (PAT), an indicator of acute 
arousal responses to OSA. The PAT signal measures the 
pulsatile finger arterial volume changes that are regulated by 
the adrenergic innervation of smooth muscles of finger vas-
culature, and thus reflects sympathetic nervous system activ-
ity. PAT may indirectly detect apnea/hypopnea events by 
identifying surges of sympathetic activation associated with 
the termination of these events. This information is further 
combined with heart rate and pulse oxymetry data that are 
considered by the automatic algorithm of the analysis sys-
tem. This detects respiratory events and calculates the PAT 
RDI [16]. Due to the cost and limited availability of full 
polysomnography in a sleep lab, in practice screening for 
OSAS is mostly based on portable polysomnographic de-
vices, often supported by the use of questionnaires [12]. 
Pathophysiology 
 Normal sleep is distinguished as rapid eye movement 
(REM) sleep or no-synchronized sleep, which occurs cycli-
cally and more frequently during the second half of the 
night, and non-REM sleep or synchronized, which is sub-
classified into four stages and the amount of sleep time. The 
four stages consist of drowsiness (stage 1), mild sleep (stage 
2) and deep sleep (stage 3-4). Decreased heart rate, blood 
pressure and sympathetic nerve activity occur during non-
REM sleep. REM sleep, instead, is characterized by in-
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creased electrical activity in the brain and sympathetic nerve 
outflow, moreover, it is connected to intermittent and abrupt 
changes in blood pressure and heart rate. In obstructive sleep 
apnea this homeostatic control is severely altered. 
 The critical pathophysiological feature of OSA is sleep-
related collapse of the upper airway (UA) at the level of 
pharynx. Obstructive apneas and hypopneas occur because 
of intermittent complete and partial collapse of pharynx, 
respectively, during sleep. Pharyngeal collapse can occur at 
the end of expiration or at the beginning of inspiration. The 
collapse initially starts in the retropalatal/oropharyngeal ar-
eas in most (56–75%) OSAS patients (57, 127). This is fol-
lowed by caudal extension of the collapse to the base of the 
tongue in 25–44% of patients (57, 127) and, finally, to the 
hypopharyngeal region in 0–33% of patients. 
 During normal sleep, some protective mechanisms assure 
partial patency of the upper airway. There are more than 20 
skeletal muscles with tonic and phasic activity that constitute 
the pharyngeal mucosa, playing a role in airway dilatation 
and wall stiffening. In REM-sleep, this activity is reduced by 
muscle atonia. Anyway, muscle activity in the upper airway 
is modulated even by chemoreceptor responses to blood 
oxygen and carbon dioxide tensions, as well as local reflex 
mechanisms, such as the negative airway pressure associated 
with vigorous inspiration. A smaller caliber upper airway 
lumen during wakefulness and sleep has been noted in pa-
tients with OSAS versus normal controls. Volumetric MRI 
suggests that most of the responsible soft tissue, that in part 
can be explained by fat deposition, originates from the 
tongue and lateral pharyngeal walls and renders vulnerable 
to collapse the upper airway of persons with OSAS. As a 
possible compensatory mechanism for this anatomically 
compromised airway, patients with OSAS have increased 
electromyographic activity of the pharyngeal dilator muscles 
during wakefulness. 
 Recent literature suggests that other variables may play a 
role in OSAS. Inflammation and trauma to the upper airway 
due to snoring, vibration, extrinsic contraction or fatigue can 
lead to a denervation of pharyngeal dilator muscles or actual 
damage to the muscles themselves. These events render the 
muscles that are less able to response to negative airway 
pressure during an apneic event [17-19]. 
 Although data are insufficient to clarify the role of nasal 
obstruction in the pathogenesis of OSAS, the nose may play 
a role in upper airways collapsibility. A nasal obstruction 
causes an increase in airflow resistance upstream from the 
collapsible portion of the pharynx. As a result, the degree of 
negative collapsing pressure is increased on inspiration, ren-
dering the pharynx more collapsible.  
 These cycles of hypoxia and carbon-dioxide retention 
elicit oscillations in both cardiac parasympathetic and sym-
pathetic nervous activity. At apnea termination, asphyxia 
triggers a brief arousal from sleep that abruptly increases 
sympathetic activity, and suppresses vagal tone, precipitating 
surges in blood pressure and heart rate. Intermittent hypoxia 
can induce oxygen-free-radical production and activate in-
flammatory pathways that impair vascular endothelial func-
tion. These adverse vascular effects, combined with in-
creased sympathetic vasoconstrictor activity and inflamma-
tion, could predispose to hypertension and atherosclerosis. 
Cerebral blood flow declines significantly during obstructive 
apneas due to a decrease in cardiac output, and in the pa-
tients with flow-limiting lesions of the cerebral arteries, this 
can predispose to ischemic events. 
 A number of studies have reported an independent asso-
ciation of OSAS with several components of metabolic syn-
drome, particularly insulin resistance and abnormal lipid 
metabolism. OSAS-related factors that may contribute to 
metabolic dysregulation include increased sympathetic activ-
ity, sleep fragmentation, and intermittent hypoxia [20, 21]. 
Therapeutical Options 
Continuous Positive Airway Pressure and Oral Appliance 
 Continuous positive airway pressure (CPAP) represents 
the main treatment of OSAS that prevents airway collapse 
during respiration at night. Other strategies for treating 
OSAS include oral appliances [22]. In the same time, it is 
very useful in treating patients with sleep disordered breath-
ing (SDB) to eliminate all possible contributing factors, in-
cluding weight loss for patients who are obese and elimina-
tion of alcohol or sedative use, especially near bedtime and 
sleep postural changes, focusing on avoidance of sleeping in 
the supine position, weight loss, avoidance of alcohol and 
sedative hypnotics intake, and upper airway surgical proce-
dures. Nasal continuous positive airway pressure (CPAP) is 
considered as an ideal treatment for treating OSAS, due to its 
being conservative and reversible, however, there is a poor 
rate of adherence in its long-term use.  
 For patients with mild and moderate OSAS patients who 
do not compliant or poorly compliant to nasal CPAP, oral 
appliance could be used. The rationale for oral appliances is 
to increase the posterior oropharyngeal airway space, there-
fore reducing upper airway collapsibility during sleep. Ap-
pliances are generally less successful with severe OSAS 
(AHI>50). Oral appliances can be classified as either tongue-
retaining or mandibular-repositioning. [23, 24].  
Medical Therapy 
 The exact target of pharmacological treatment for OSAS 
still remains to be defined, and currently, no widely accepted 
pharmacological treatment is available for OSAS [25]. Sev-
eral potential drug candidates in OSA have already been 
investigated, but most of the trials have limited in size, and 
only few met the quality criteria applied in a drug study. 
Among the drugs, we have non-sedating tricyclic antidepres-
sant protriptyline, the serotonin precursor L-tryptophan, the 
cholinesterase inhibitory agent physostigmine, theophylline, 
aminophylline, and acetazolamide [26-29].  
 Ideally, the medical treatment of OSAS should include 
not only the improvement of nocturnal breathing, but also of 
comorbid conditions such as hypertension, obesity, meta-
bolic derangement, hormonal dysfunction, daytime sleepi-
ness, and cognitive dysfunction [30]. 
 Surgery can significantly complement those cases where 
CPAP is not tolerated (long-term compliance is not more 
than 50% due to several side effects), alleviate symptoms of 
daytime sleepiness, improve quality of life, and reduce the 
signs of sleep apnea recorded by polysomnography. The goal 
122    Current Genomics, 2009, Vol. 10, No. 2 Casale et al. 
of surgical correction in the upper airway is to reduce the 
number and severity of obstructive events, when complete 
elimination of these events is not possible. Surgery for 
OSAS must be carried out taking the degree of obstructive 
apnea, and the place of greatest obstruction into account. 
Most OSAS patients have multilevel disease including nasal 
and retrolingual obstructions, and due to this reason the ap-
propriate surgical treatment should be multileveled. In the 
last decade, a significant increase in publications on multi-
level approach for OSAS patients illustrated the trend, away 
from single-level surgery. We have many surgical proce-
dures from mini-invasive interventions for mild forms to 
more aggressive ones for severe OSAS cases [31]. 
 The operative techniques included the following: 
1.  Nose—submucosal resection of septum and inferior 
turbinate, endoscopic sinus surgery, polypectomy, radiof-
requency (RF) turbinate surgery, and nasal valve suspen-
sion. 
2.  Oropharynx—uvulopalatoplasty, tonsillectomy, transpala-
tal advancement pharyngoplasty, uvuloflap, uvulopalatal 
flap, extended uvulopalatal flap, laser-assisted uvu-
loplasty, RF palatal surgery, and Pillar implant technique. 
3.  Hypopharynx—maxillomandibular advancement, partial 
glossectomy, laser lingual tonsillectomy, genioglossus 
advancement, hyoid suspension, tongue base reduction 
with hypoepiglottoplasty, partial epiglottidectomy, hyoid 
suspension to the mandible, thyrohyoid advancement, 
tongue base suspension with the repose system, and RF 
tongue reduction [32]. 
MAIN RISK FACTORS: THE GENETIC BASIS  
 Several previous reports have described OSAS occurring 
in genetically related subjects. Strohl et al. first described a 
family with multiple male relatives suffering from the symp-
toms of excessive daytime sleepiness and night time rest-
lessness, from which three brothers had repetitive apneas 
during sleep [33]. 
 Familial aggregation is generally explained by the fact 
that most risk factors involved in the pathophysiology of 
OSAS are, to a large extent, genetically determined.  
 The prevalence of OSAS is typically higher among cer-
tain ethnic groups, such as African-Americans, in which it 
appears to present at a younger age and may also be more 
severe than European-Americans. Redline et al., in a case-
control family study, described the distributions of sleep-
disordered breathing (SDB) in African-Americans and Cau-
casian. This study showed how African-Americans with 
SDB were younger than Caucasians with SDB (37.2 +/- 19.5 
versus 45.6 +/- 18.7 yr, p < 0.01) and how, RDI level was 
higher in subjects < or = 25 years old in African-Americans 
[19]. Racial variations may be due to obesity that is more 
prevalent and more epidemic in African-Americans than in 
European-Americans. Anatomic features typical of each race 
like the increased upper airway soft tissue in African-
Americans seems to play also an important role. 
 In a similar study, Baldwin et al., considered sleep re-
lated breathing disorders in Maori-Pacific Islanders and 
Europeans. Higher levels of severity parameters of OSAS 
(apnea-hypopnoea index, wake and minimum oxygen satura-
tion, and apnea duration) were seen in both Maori and Pa-
cific Islanders than Europeans [34].  
 The major risk factors for OSAS include obesity, ventila-
tory control abnormalities, and craniofacial dysmorphism 
(disproportionate craniofacial anatomy).72 [35]. To address 
the issue of genetic predisposition to OSAS, two basic de-
signs are currently used: a systematic genome scan in multi-
plex families, and the study of candidate gene markers by 
case-control designs [36].  
Body Weight and Fat Distribution  
 There are several factors that increase the risk of OSAS 
development in general population. Among these, obesity is 
the most common clinical finding and it is present in more 
than 60% of the patients with OSAS [37]. Peppard et al. in a 
prospective study illustrate a relation between weight gain 
and OSA severity [38]. In particular, they found that a 10% 
weight gain is associated with an approximate 32% increase 
in the AHI and a 10% weight loss is associated with a 26% 
decrease in the AHI. However, the real causal pathways in-
volved in the relationship between obesity and OSAS are not 
completely defined. Some studies proposed that hormonal 
mechanism may leads to the development of OSAS in the 
patients with obesity. In fact, adipose tissue produces leptin, 
a hormone that has an important effect on weight regulation 
by stimulation of hypothalamic satiety centers. O'Donnell et 
al. reported an important role for leptin in stimulating venti-
lation in the experiments using obese mouse mutated for the 
gene that encodes leptin [39]. In this way, a state of leptin 
resistance in obese subjects suggested by Considine et al. 
[40] may represents one of the causes of higher prevalence 
of OSAS in these patients. 
 Many studies have shown that there are some genes in-
volved in the development of both obesity and OSA. Clearly, 
given the close relationship between obesity and OSAS, any 
genetic risk factor for obesity might also be considered a risk 
factor for OSAS. 
 A candidate gene is placed on chromosome 2, encoding 
for pro-opiomelanocortin (POMC). This is a pro-hormone 
that is converted in melanocyte-stimulating hormones (a-
MSH) by proconvertase 1, and plays an important role to 
mediate the effects of leptin on appetite reduction, on in-
crease of energy expenditure and on ventilatory drive. An-
other potential candidate gene is the COH1. It is located on 
the long arm of chromosome 8 and encodes a transmembrane 
protein that seems to be involved in vesicle-mediated sorting 
and intracellular transport [41]. Even if severe mutations in 
this gene causes the Cohen syndrome, characterized by men-
tal retardation, microcephaly, prominent nose and short and 
upturned philtrum, truncal obesity, joint laxity, etc., only 
mild mutation in this one might be involved in a non-
syndromic form of obesity and OSAS as suggested by Patel 
SR [42]. There are a number of studies showing the in-
volvement of serotoninergic system in the development of 
both obesity and OSAS. This system is known to modulate 
mood, emotion, sleep, and appetite. In particular, serotonin 
stimulates the satiety center placed in arcuate nucleus and it 
excites adult upper airway dilator motor neurons [43]. For 
these reasons it is easy to understand how the reduction in 
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serotoninergic activity leads to an increase in appetite and to 
a reduction in upper airway muscle tone, and in this way to 
obesity and OSAS. Miina Öhm et al., in a study conducted in 
Finnish population, suggest that a major locus affecting obe-
sity phenotype would lie on chromosome Xq24 [44]. In 2003 
Suviolahti et al. investigated the Xq22–24 region and found 
significant evidence of association between obesity and a 
polymorphism of SLC6A14 gene. It encodes Na- and Cl-
dependent membrane protein involved in the transport of 
tryptophan, the precursor of serotonin, across the plasma 
membrane into CNS [45]. This association was also con-
firmed in a French study conducted by Durand et al. [46]. 
 Body fat distribution plays an important role in the de-
velopment of OSAS. It is easy to understand that the fat 
deposition in upper airway lumen may increase its collapsi-
bility. Shinohara et al. suggest that visceral obesity is associ-
ated more often with OSAS rather than other forms of obe-
sity [47]. They consider that the mass weight of visceral fat 
may cause an increase in the activities of the inspiratory 
muscles by restricting the motion of the diaphragm. This 
results in increased inspiratory negative airway pressure 
leading to collapse in the upper airway. BMI (Body Mass 
Index) is the most common parameter to describe obesity 
worldwilde and many studies suggest the strength of this 
index to predict OSAS [4, 48]. There are some available an-
thropomorphic measurements to predict the presence of 
OSAS and its severity. Dixon et al. consider the neck cir-
cumference as the best single measure for predicting OSAS. 
For Schafer et al. the percentage of body fat, measured by 
BIA (Bioelectrical Impedance Assay), and BMI are the only 
significant predictors for OSAS. Ögretmenoglu et al. consid-
ered the percentage of body fat and BMI as important pa-
rameters for predicting OSAS and also proved the relation-
ship between visceral abdominal fat, measured by CT, and 
AHI [48]. It must be considered that not all forms of obesity 
play the same role in the development of OSAS. In particu-
lar, fat deposition in the neck and the typical fat deposition 
pattern of male gender (in the subcutaneous regions of torso 
and abdomen) could be considered as predictors of OSAS 
[49]. In 2000, Katzmarzyk et al. estimated the level of famil-
ial similarity in anthropometric indicators of fatness and fat 
distribution and found a heritabilities of 29–48% for three 
indicators of fat distribution: BMI-adjusted waist circumfer-
ence and ratio of trunk to extremity skinfold ratio [50]. These 
findings suggest the role of genes in explaining at least part 
of the heritability. 
Craniofacial Morphology 
 Several studies demonstrated the relationship between 
many morphological factors and OSAS. About the skeletal 
morphology, it was found that SNA and SNB values were 
significantly reduced in patients with OSAS, suggesting a 
link between retrognathia, micrognathia and this disease 
[51]. Also an increase in soft palate thickness, length and 
area, in tongue’s length and area and in intermaxillay space 
length, leads to the reduction of size of the upper airway and 
so to higher risk of OSAS [51]. Riha et al. also found that a 
lower-set hyoid bone in relation to the mandibular plane is 
significantly associated with a diagnosis of OSAS [52]. In 
fact, the hyoid bone, where the attachments of the lingual 
musculature are located, pulls down the tongue leading a 
narrowing of the pharyngeal airway.  
 Inherited abnormalities of craniofacial structure appear to 
explain at least a portion of the familial clustering of OSAS, 
and the genetic basis is suggested by twin and family studies. 
 Mathur et al. revealed that relatives of OSAS patients 
showed total narrow pharyngeal volumes and glottic cross-
sectional areas, retropositioned maxillae and mandibles, and 
longer soft palates as compared with the relatives of controls 
[53].  
 Guilleminault et al. found that OSAS patients have some 
mild craniofacial disproportions, and in 1986, they published 
that infants with apparently life-threatening events and sleep 
apnea typically have family members with obstructive sleep 
apneas and that small upper airways, indicated by cephalo-
metric roentgenograms and volume CT scans, were a com-
mon familial feature. 
 In a large study published in 1995 Guilleminault et al. 
showed that a disproportionate craniofacial anatomy was 
common in familial groups with OSAS, concluding that cra-
niofacial familial features can be a strong indicator of risk 
for the development of OSAS [54].  
 There are many genetic syndromes associated with a 
number of craniofacial dysmorphisms and it could be con-
sidered another link between genes and OSAS. One of these 
is Down’s syndrome in which OSAS is very common. Mar-
fan syndrome, carried by a gene called FBN1, which 
encodes a connective protein fibrillin-1, may also causes 
craniofacial dysmorphisms and upper airway connective 
tissue laxity, and in this way OSAS [55]. Craniofacial ab-
normalities such as retrognathia and micrognathia were no-
ticed in mice deficient in endothelin-1 [56], with mutations 
of the retinoic acid receptors (RARs) [57] and of transform-
ing growth factor-beta2 (TGFbeta2) [58]. 
Respiratory Control System  
 The presence of ventilatory instability in OSAS patients 
was first noted when periodic breathing accompanied by 
central apneas, occurred after tracheostomy [59]. 
 Induction of periodic breathing during sleep by hypoxia, 
but only in the presence of inspiratory resistive loading, can 
induce UA obstruction in normal subjects [60].  
 It is possible that ventilatory patterns are modified during 
hypercapnia or hypoxemia through chemoreflexes control.  
 Peripheral chemo receptors, the most important of which 
are located in the carotid bodies of the internal carotid arter-
ies, primarily respond to blood oxygen tension, while brain-
stem central chemo receptors are most sensitive to carbon 
dioxide and acid-base balance. In healthy persons, the 
chemoreceptor response is reduced during sleep as compared 
with wakefulness, and it leads to modest changes in blood 
gas tensions (increase in partial pressure of carbon dioxide of 
2 to 6 mmHg and decrease in oxygen saturation of up to 
2%). Some studies have shown that patients with OSAS have 
a greater peripheral chemoreflex sensitivity, producing an 
increased ventilatory response to hypoxemia. Enhanced 
chemoreflex sensitivity in OSAS may explain the exagger- 
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ated sympathetic response during hypoxemic episodes. In 
healthy persons, there are interactions between the chemore-
flex and baroreflex responses. The baroreflex attenuates ven-
tilatory, sympathetic, and bradycardic responses to periph-
eral chemoreflex excitation. Baroreflex dysfunction causes a 
disinhibition of chemoreflex responses, it can occur in hy-
pertension or heart failure and may have relevance when 
cardiovascular disease coexists with OSAS [3]. 
 A hallmark of OSAS is a marked reduction in pleural 
pressure, because of respiratory efforts against a restricted or 
collapsed airway. 
 Some research groups have noted that potentially inher-
ited abnormalities of ventilatory control may predispose to 
obstructive or central sleep apnea by influencing ventilation 
during sleep and increasing the propensity to upper airway 
collapse. Altered ventilatory drive also may precipitate apnea 
by promoting ventilatory control instability and, subse-
quently, periodic breathing. Ventilatory control instability 
could result from either blunted or augmented chemosensi-
tivity. 
 An inherited basis for ventilatory responsiveness to hy-
poxemia or hypercapnia has been suggested by the findings 
from several human studies. Troubles in ventilatory re-
sponses to hypoxia or hypercapnia have been described in 
the first degree relatives of the people with various pulmo-
nary diseases or syndromes. Several twin studies have dem-
onstrated similarities in ventilatory responses to hypoxia or 
hyperoxia to be greater in MZ than in DZ twins, concluding 
a genetic basis for the chemoresponse to blood oxygen satu-
ration [61]. 
 Heritability for chemoresponsivity to oxygen saturation 
levels vary between approximately 30% and 75%, suggest-
ing a substantial contribution of inheritance to this trait. A 
greater reduction of ventilatory responses to progressive eu-
capnic hypoxia during wakefulness is observed in the mem-
bers of OSAS families as compared to members of control 
families. Moreover, impairment in load compensation was 
suggested by the finding of a significantly greater increase in 
ventilatory impedance with inspiratory resistive loading in 
OSAS family members versus control subjects [62]. These 
data point out that the familial aggregation of OSAS may be 
based on inherited abnormalities in ventilatory control, 
probably related to chemoregulation and/or load compensa-
tion. In genetically susceptible individuals, the upper airway 
appears sensitive to excess collapsibility during conditions of 
mild inspiratory loading. Some clues regarding the underly-
ing genetics of ventilatory control abnormalities in OSAS 
may be gleaned from studies of children with congenital 
central hypoventilation (CCH) syndromes. These are chil-
dren with frequent apneas and daytime hypoventilation, at-
tributable to severe chemoregulatory dysfunction, because of 
profound blunting of the hypercapnic and hypoxic ventila-
tory responses. In some cases, developmental abnormalities 
of the brainstem or cerebral cortex have been found. In the 
absence of secondary causes, they are labeled as “idiopathic 
congenital central hypoventilation”. Familiarity in CCH has 
been described and several analyses suppose that the disor-
der can be explained by either multifactorial threshold or 
major locus models. Hirschsprung’s disease, congenital dis-
order with intestinal dysmotility and absence of myenteric 
and submucosal ganglia in the distal bowel, may occur in as 
many as 50% of cases of CCH [63]. 
 In children with Hirschsprung’s disease, mutations of 
both the RET proto-oncogene have been described, encoding 
a receptor tyrosine kinase that is thought to be involved in 
neural crest migration and proliferation, and RET ligand, 
glial cell line-derived neurotrophic factor (GDNF) [64]. 
 So, it is possible that CCH syndromes may be sometimes 
caused by abnormalities in migration of neural crest cells to 
central respiratory control centers. Moreover, other genes 
involved in the endothelin signaling pathway (endothelin B 
receptor gene, EDNRB and endothelin 3 gene, EDN3) have 
been implicated in Hirschsprung’s disease and could be con-
sidered as candidate genes for CCH syndromes and sleep 
apnea. Endothelin-1 (ET-1), a potent vasoactive peptide, 
may participate the control of ventilation. In a knockout 
mouse model, absence of ET-1 results in respiratory failure, 
ventilatory control abnormalities, craniofacial abnormalities 
and hypertension; characteristics remarkably similar to traits 
found in OSAS [56]. 
 A European group has demonstrated that when the zinc 
finger protein Krox-20 is deleted, mice show slow respira-
tory frequencies and long apneas. Another group of re-
searchers has seen a reduced survival of neurons in the no-
dose-petrosal ganglion, when they study knockout mouse 
model of brain derived neurotrophic factor (BDNF). Any-
way, homozygous mice for BDNF alterations demonstrate 
irregular and depressed ventilation, spontaneous apneas and 
abnormalities in chemoregulation, specifically related to 
hyperoxia but not to hypercapnia [65]. 
 Together these data show the complexity of the respira-
tory control system, and that a number of genes, important in 
different native regulatory functions, may influence ventila-
tory phenotypes. 
 Other candidate genes include a family of genes that en-
code neuroreceptors (e.g., glycine receptor, glutamate recep-
tor), and genes that influence the post-natal development of 
the lung (e.g. basic fibroblast growth factor, bFGF). Some 
groups have examined breathing frequency during hypoxia 
and proposed a two-gene model, involving genes that are 
different from those that determine baseline frequency [66]. 
Finally, another probable link between respiratory control 
and the 8q22 chromosomal region has been observed. It con-
tains three genes for carbonic anhydrase (CA) isoenzymes: 
CA1, CA2, and CA3. Several animal and human studies are 
going to confirm the roles of CA in modulating respiratory 
control, and the role of CA inhibitors as potential treatment 
for conditions as respiratory instability, sleep periodic 
breathing, and OSA [67].  
CONCLUSION 
 There is a continuous interaction in the structural devel-
opment of the upper airway region, between genetic and en-
vironmental factors. Clinical and epidemiological studies 
show that OSAS is a multifactorial and complex disease with 
a strong genetic basis. Many genes are involved, from genes 
that induce migration of specific cellular groups to genes 
leading to the structural organization The identification of 
genes implicated through human and animal models in 
Obstructive Sleep Apnea Syndrome Current Genomics, 2009, Vol. 10, No. 2    125 
OSAS would help to elucidate the OSAS pathogenetic proc-
esses, still largely obscured. 
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